SCHEMBL4482469

SCHEMBL4482469

COCC(=O)N(CCN(C)C)c1ccc(N)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHLPP2 Q6ZVD8 1/20 0.44
MLYCD O95822 1/20 0.40
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
RECQL P46063 1/20 0.38
HPGD P15428 2/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ROCK2 O75116 1/20 0.38
ATM Q13315 1/20 0.38
PKM P14618 1/20 0.38
TP53 P04637 2/20 0.37
PPIB P23284 1/20 0.36
CYP3A4 P08684 2/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14174754 0.88 KDM4E (0.48) MLYCDALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL3146589 0.83 PHLPP2 (0.44) PHLPP2MLYCDALDH1A1SMN1; SMN2RECQL
SCHEMBL3147820 0.80 TP53 (0.61) PHLPP2MLYCDALDH1A1SMN1; SMN2RECQL
SCHEMBL3941842 0.79 PPIB (0.52) PHLPP2MLYCDALDH1A1KDM4EHSD17B10
SCHEMBL3142097 0.79 PHLPP2 (0.46) PHLPP2MLYCDALDH1A1SMN1; SMN2RECQL
SCHEMBL14174973 0.79 KDM4E (0.44) ALDH1A1KDM4EHSD17B10SMN1; SMN2POLB
SCHEMBL3156492 0.77 CNR2 (0.49) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL3143717 0.75 MEN1 (0.49) PHLPP2ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL3143768 0.75 MLYCD (0.62) PHLPP2MLYCDALDH1A1KDM4ERECQL
SCHEMBL55543 0.75 PHLPP2 (0.43) PHLPP2MLYCDALDH1A1SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR PHLPP2 1485/4885MLYCD 4039/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.